针对性去甲基化和NLRC5的激活通过MHC I类增强癌症免疫性
Xin Sun1, Toshiyuki Watanabe1, Yoshitaka Oda2
1Department of Immunology, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
概括
研究人员开发了CRISPR/Cas9系统TRED-I,以促进癌症中主要基因相容性复合体 (MHC) 的I类表达. 这种方法增强了抗瘤免疫力,并改善了对免疫疗法的反应,提供了一个有前途的新癌症治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 缺陷主要基因相容性复合体 (MHC) I类表达是癌症免疫逃避机制的关键.
- 低MHC I类水平与预后不佳和对检查点阻塞疗法的耐药性相关.
- 存在有限的治疗策略,专门诱导MHC I类表达.
研究的目的:
- 开发一种新的系统,可对MHC I类表达进行强有力的和特定的诱导.
- 调查针对MHC I类交换激活器 (CITA) /NLRC5.5的治疗潜力.
主要方法:
- 开发了一种基于CRISPR/Cas9的基因特异性系统TRED-I (针对MHC-I的定向活性化和脱甲基化).
- 在TRED-I系统中,将去甲基化酶和转录激活剂招募到NLRC5促进体中.
- 利用动物癌症模型来评估TRED-I系统的有效性.
主要成果:
- 该TRED-I系统成功诱导了MHC类I表达,增强了抗原呈现.
- 在瘤微环境中证明了加快的CD8+T细胞激活和透.
- 观察到显著的瘤抑制作用和抗PD1检查点阻塞疗法的有效性提高.
结论:
- 通过TRED-I系统准NLRC5是癌症治疗的可行策略.
- 这种方法通过恢复MHC I类表达来增强抗瘤免疫力.
- 在TRED-I系统显示了与检查点阻塞剂的组合治疗的潜力.
相关概念视频
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K